Building the future together - making healthcare sustainable

Marketing document only intended for professional investors as defined by MIFID



Marketing communication related to HSBC GIF Global Equity Sustainable Healthcare, a sub-fund of HSBC Global Investment Funds, a distributed SICAV This document is intended for Professional Clients as defined by MIFID only and should not be distributed to or relied upon by Non professional clients, he information contained in this document is not intended as investment advice or recommendation. UCITS Sicav managed by HSBC Investment Funds (Luxi) A Non contractual document



Together we thrive

HSBC GIF Global Equity Sustainable Healthcare

Building the future together – making healthcare sustainable

A thematic fund that aims to drive social impact without sacrificing performance

An approach based on sustainability, innovation and long-term growth





- ly managed under a Swiss certificate before the launch in the HSBC GIF Luxembourg SICAV
- United Nations Sustainable Development Goals
- EU Sustainable Finance Disclosure Regulation Article 8 product = a financial product promotes, among other characteristics, environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices

Why invest in HSBC GIF Global Equity Sustainable Healthcare?

Successful track record of managing Rising healthcare costs resulting in healthcare equity strategies access restrictions hurts patients Trend Extensive healthcare experience Access restrictions negatively Team having held executive positions impact company revenues, threaten in the pharmaceutical and to break the innovation cycle and biotechnology industries thus the sustainability of healthcare Co-Heads Healthcare Dr. Nathalie Flury Dr. Michael Schröter Aligned with UN SDG goal 3 on "Good health and wellbeing" Making healthcare sustainable by **Theme** Time addressing all stakeholders needs Focus on healthcare companies to act (from patient to shareholders) offering affordable innovation with distinct clinical differentiation



We believe that investing in the companies at the forefront of delivering Sustainable Healthcare will provide you with excellent returns whilst also helping to achieve good health and wellbeing.

Source: HSBC Asset Management, May 2021. For illustrative purposes

The commentary and analysis presented in this document reflect the opinion of HSBC Asset Management on the markets, according to the information available to date. They do not constitute any kind of commitment from HSBC Asset Management. Consequently, HSBC Asset Management will not be held responsible for any investment or disinvestment decision taken on the basis of the commentary and/or analysis in this document

Trend - Rising healthcare costs



A global healthcare challenge



Global demographic trends + Rising healthcare costs

- >
- Straining healthcare systems globally
- Enhancing the demand for sustainable healthcare solutions and products



Impacts: Healthcare access restrictions

Raising healthcare expenditures strain healthcare budgets forcing payers worldwide to increase access restrictions



43% of patients missed a dose due to cost or other factors

Access restrictions hurt patients, physicians, industry and investors



Consequence: healthcare system change

The healthcare system has begun to undergo massive and rapid changes to become more sustainable from a cost point of view



Opportunities: innovations

New investment opportunities in scientific, technological, and business innovation that address both improved patient outcomes and cost effectiveness at the same time



Great innovation in healthcare but who can afford it?

Source: HSBC Asset Management, May 2021. For illustrative purposes. The commentary and analysis presented in this document effect the opinion of HSBC Asset Management on the markets, according to the information available to date. They do not constitute any kind of commitment from HSBC Asset Management. Consequently, HSBC Asset Management will not be held responsible for any investment or disinvestment decision taken on the basis of the commentary and/or analysis in this document. Any forecast, projection or target where provided is indicative only and is not guaranteed in any way. HSBC Asset Management accepts no liability for any failure to meet such forecast, projection or target.

Time to act - Making healthcare sustainable





Past strategies to make healthcare sustainable no longer work

Are we reaching the tipping point that jeopardises healthcare sustainability?



In order for a healthcare system to be sustainable, all stakeholder needs must be addressed





Theme - HSBC Sustainable Healthcare investing




An innovative approach

What is HSBC Sustainable Healthcare?


1. A thematic strategy that aims to achieve a socially responsible investment in healthcare without sacrificing financial performance, is in line with Goal 3 of United Nations Sustainable Development Goals



- 2. Classified Article 8 under the EU Sustainable Finance Disclosure Regulation
- 3. High conviction & bottom-up analysis paired with macro-economic trend
- 4. Sustainable, long-term growth oriented



Innovations in healthcare sector: New treatments, devices, diagnostics, digital-health and services can reduce overall healthcare cost



Sustainable Healthcare strategy

Focus on macroeconomic trend of sustainable healthcare differentiates our investment approach

Theme - HSBC Sustainable Healthcare investing

In practise: Integrated ESG + proprietary sustainability index

Investment process

Thematic – healthcare or 2/3 of sales from healthcare **Investable Universe** Exclusion of companies engaged in controversial 600 companies activities (e.g. chemical and biological weapons) Qualitative analysis - product, competition, social factors **Investment Universe** Quantitative analysis – market growth potential, valuation 250 companies Regulatory and clinical analysis – clinical trials, **Regulatory & Clinical** comparison to standard of care, milestone events 150 companies Market access analysis - affordability, health **Market Access** economics, cost savings potential, budget impact potential & Pricing 90-120 companies ESG scores augmented by proprietary sustainability index based on clinical differentiation and cost savings potential **Portfolio**

Source: HSBC Asset Management. For illustrative purposes only.

35-40 companies

The commentary and analysis presented in this document reflect the opinion of HSBC. Asset Management on the markets, according to the information available to date. They do not constitute any kind of commitment from HSBC. Asset Management. Consequently, HSBC Asset Management will not be held responsible for any investment or disinvestment. decision taken on the basis of the commentary and/or analysis in this document. Representative overview of the investment process, which may differ by product, client mandate or


Active engagement with company management

Theme - HSBC Sustainable Healthcare investing



HSBC's 1st strategy to market

A solid 2-year global equity performance with in-depth expertise in the healthcare sector




MSCI Total Return Net Healthcare Index ²	9.9	13.5
1Y Rolling performance - gross (%)	30.06.2020 - 30.06.2021	30.06.2019 - 30.06.2020
Sustainable Healthcare Strategy	16.0	26.2
MSCI Total Return Net Healthcare Index ²	23.0	13.8

¹ Strategy inception 26^h April 2019. Gross returns. Data as at end June 2021 ² Reference index represents the healthcare market sector and is used for comparison purposes only.

46.6

Deep fundamental research with integrated proprietary cost-savings analysis enables us to deliver a portfolio focused on 30-60 stocks, diversified across all healthcare sub-sectors with no fix allocations across geographies, sub-subsectors, company stages, and/or profitability.



Source: Bloomberg and Viopas Partners AG, as at 30 June 2021. For illustrative purposes only.

Past performance are no guarantee of future returns. Future returns will depend inter alia on market developments, the fund manager's skill, the fund's level risk and management costs and if applicable subscription and redemption costs. The return, the value of money invested in the fund may become negative as a result of price losses and currency fluctuations. There is no guarantee that all of your invested capital can be redeemed. Unless stated otherwise, inflation is not taken into account.

Main risks: Capital loss risk, Equity risk, Discretionary management risk, Foreign exchange risk, Small & Mid cap risk The performances are displayed gross of fees. The application of the fees will have the effect of reducing the performances presented. Allocation is as at the date indicated, may not represent current or future allocation and is subject to change without prior notice.

Team - Experienced and complementary



Harnessing HSBC's global resources for ESG, equity analysis and engagement



In depth Sustainable Healthcare Expertise

- Two Co Heads of Sustainable Healthcare Equity that have worked together for a long time
- 20+ years average experience in Equity investing and pharma and biotech sectors
- Launched 1st Sustainable Healthcare investment strategy in the market

Access to extensive resources

- Leverage on proprietary insights driven by experienced and well resourced research of 82 equity analysts and 194 equity portfolio managers based around the world including 73 in Asia
- More than 15 experts in ESG research and Engagement teams

Source: HSBC Asset Management, May 2021. For illustrative purposes

Dr. Nathalie Flury

20+ years experience as a fund manager managing 4 European based biotech and healthcare Lux. SICAV mutual funds and track record with custom made biotech and medtech mandates for family offices

- Viopas: Healthcare Sustainable AMC & Mandate
- Pictet: Pictet Health Fund, Pictet Biotech Fund
- Julius Baer Bank / GAM: JB Health Innovation Fund
- Clariden Bank: Clariden Biotech cross-over Fund

Dr. Michael Schröter

20+ years experience in Pharma and Biotech in executive positions in access & pricing, R&D, business development & licensing in US, Asia and EU

- Viopas: Healthcare Sustainable AMC & Mandate
- Roche: Head Innovative pricing, Head external R&D
- Eli Lilly: Business Development, Head oncology diagnostic R&D center
- Apotech: Biotech co-founder



Dr. Nathalie Flury




Dr. Michael Schröter

Fund details

Fund domicile	UCITS, Luxembourg SICAV	
Fund launch date Strategy launch date	July 2021	
Strategy laurion date	23 April 2019	
Base currency	USD	
ISIN	AC: LU2324357040	
	IC: LU2324357396	
Fees (maximum)	Management fees	
	AC: 1.50% IC: 0.75%	
	Operating, Administrative & Servicing Expenses	
	AC: 0.35% IC: 0.25%	
Minimum initial investment	AC: USD5,000	
	IC: USD1,000,000	

Key risks

- Capital loss risk: It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed.
- Equity risk: Funds that invest in securities listed on a stock exchange or market could be affected by general changes in the stock market. The value of investments can go down as well as up due to equity markets movements.
- Discretionary management risk: Discretionary management is based on anticipating the evolution of different markets and securities. There is a risk that the fund will not be invested at any time in the most efficient markets and securities.
- Foreign Exchange risk: Where overseas investments are held, the rate of exchange of the currency may cause the value to go down as well as up. Variations in exchange rates between currencies can have a significant impact on the performance of the products presented.
- ♦ Small & Mid cap risk: Please note that the fund is invested in securities issued by companies which, due to their small or mid market capitalization, are less liquid and may present higher risks.





The rating is based on price volatility over the last five years, and is an indicator of absolute risk. Historical data may not be a reliable indication for the future. The value of an investment, and any income from it, may fall as well as rise, and you may not get back the amount you originally invested. The rating is not guaranteed to remain unchanged and the categorisation may shift over time. The lowest rating does not mean a risk-free investment.

Important information

This presentation is distributed by HSBC Asset Management and is only intended for professional investors as defined by MIFID. The information contained herein is subject to change without notice. All non-authorised reproduction or use of this commentary and analysis will be the responsibility of the user and will be likely to lead to legal proceedings. This document has no contractual value and is not by any means intended as a solicitation, nor a recommendation for the purchase or sale of any financial instrument in any jurisdiction in which such an offer is not lawful.

The commentary and analysis presented in this document reflect the opinion of HSBC Asset Management on the markets, according to the information available to date. They do not constitute any kind of commitment from HSBC Asset Management. Tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Capital is not guaranteed. It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed. Consequently, HSBC Asset Management will not be held responsible for any investment or disinvestment decision taken on the basis of the commentary and/or analysis in this document.

All data from HSBC Asset Management unless otherwise specified. Any third party information has been obtained from sources we believe to be reliable, but which we have not independently verified. The capital is not guaranteed.

Source: MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain for making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided as an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively 'the MSCI Parties') expressly disclaims all warranties((including, without limitation, all warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.mscibarra.com).

If you have any doubts about the suitability of this investment, you should contact an independant financial adviser

HSBC Asset Management is the brand name for the asset management business of HSBC Group, which includes the investment activities provided through our local regulated entities.

HSBC GIF Global Equity Sustainable Healthcare is a sub fund of HSBC Global Investment Funds, a Luxemburg domiciled SICAV. Before subscription, investors should refer to Key Investor Document (KIID) of the fund as well as its complete prospectus. For more detailed information on the risks associated with this fund, investors should refer to the complete prospectus of the fund. The shares of HSBC Global Investment Funds have not been and will not be offered for sale or sold in the United States of America, its territories or possessions and all areas subject to its jurisdiction, or to United States Persons.

Important information for Swiss investors: This document may be distributed in Switzerland only to qualified investors according to Art. 10 para 3, 3bis and 3ter CISA. The presented fund is authorised for distribution in Switzerland in the meaning of Art. 120 CISA. (Potential) investors are kindly asked to consult the latest issued Key Investor Information Document (KIID), prospectus, articles of incorporation and the (semi-)annual report of the fund which may be obtained free of charge at the head office of the representative: HSBC Global Asset Management (Switzerland) AG, Gartenstrasse26, P.O. Box, CH-8002 Zurich. Paying agent in Switzerland: HSBC Private Bank (Suisse) SA, Quai des Bergues9-17, P.O Box 2888, CH-1211 Genève 1.

HSBC Global Asset Management (France) - 421 345 489 RCS Nanterre. Portfolio management company authorised by the French regulatory authority AMF (no. GP99026) with capital of 8.050.320 euros, in Italy, Spain and Sweden through the Milan, Madrid and Stockholm branches of HSBC Global Asset Management (France), regulated respectively by Banca d'Italia and Commissione Nazionale per le Società e la Borsa (Consob) in Italy, the Comisión Nacional del Mercado de Valores (CNMV) in Spain and the Swedish Financial Supervisory Authority (Finansinspektionen) in Sweden.

Postal address: 38 avenue Kléber 75116 PARIS - Offices: Immeuble Coeur Défense - 110 esplanade du Général de Gaulle - La Défense 4 - 92400 Courbevoie - France

www.assetmanagement.hsbc.com/fr AMFR_2021_EXT_BR_0355. Expires: 05/2022

Non contractual document, updated in: May 2021 - Copyright: All rights reserved © HSBC Global Asset Management (France), 2021.